ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

2017 ACR/ARHP Annual Meeting

November 3-8, 2017. San Diego, CA.

View by Number View by Title View Sessions
View by Date

Tuesday, November 7, 2017

9:00AM-11:00AM
Abstract Number: 2532
The Relationship between the Degree of Skin Involvement and Joint Activity in Patients with Psa: Experience from the Corrona Registry
Spondyloarthropathies and Psoriatic Arthritis – Clinical Aspects and Treatment Poster III: Outcomes, Outcome Measures, and Comorbidities
9:00AM-11:00AM
Abstract Number: 2194
The Relationship between the Number of Prescription Medications and Physical Activity Amongst Patients with or at High Risk for Knee Osteoarthritis
Osteoarthritis – Clinical Aspects Poster II: Observational and Epidemiological Studies
9:00AM-11:00AM
Abstract Number: 2541
The Relationship between the Patient Acceptable Symptom State (PASS) and Disease Activity in Patients with Psoriatic Arthritis (PsA)
Spondyloarthropathies and Psoriatic Arthritis – Clinical Aspects and Treatment Poster III: Outcomes, Outcome Measures, and Comorbidities
9:00AM-11:00AM
Abstract Number: 2386
The Risk Factors of Newly Developing/Worsening Pulmonary Abnormalities in Rheumatoid Arthritis
Rheumatoid Arthritis – Clinical Aspects Poster III: Comorbidities
9:00AM-11:00AM
Abstract Number: 1964
The Risk of Hydroxychloroquine Toxic Retinopathy and Its Risk Factors in the Treatment of Rheumatic Diseases: A Systematic Review
Epidemiology and Public Health Poster III: Rheumatic Disease Risk and Outcomes
9:00AM-11:00AM
Abstract Number: 2186
The Role of Hip Injury in Pain Exacerbation in Hip Osteoarthritis: an Internet-Based Case-Crossover Study
Osteoarthritis – Clinical Aspects Poster II: Observational and Epidemiological Studies
9:00AM-11:00AM
Abstract Number: 2595
The Role of Hydroxychloroquine in the Treatment of Undifferentiated Connective Tissue Disease
Systemic Lupus Erythematosus – Clinical Aspects and Treatment Poster III: Therapeutics and Clinical Trial Design
9:00AM-11:00AM
Abstract Number: 2497
The Role of Individual and Country-Level Socio-Economic Factors in Work Participation in Patients with Spondyloarthritis across 22 Countries Worldwide: Results from the Comospa Study
Spondyloarthropathies and Psoriatic Arthritis – Clinical Aspects and Treatment Poster III: Outcomes, Outcome Measures, and Comorbidities
9:00AM-11:00AM
Abstract Number: 2575
The Role of Interferon in Autoimmune-Susceptible Ro60 Knockout Mice
Systemic Lupus Erythematosus – Animal Models Poster
9:00AM-11:00AM
Abstract Number: 2233
The Role of Life Purpose in Disability and Depression in Patients with Acute Low Back Pain
ARHP Pain – Clinical Aspects Poster
9:00AM-11:00AM
Abstract Number: 2648
The SLE Risk Variant, Reference Single Nucleotide Polymorphism (rs)10499197, Upstream of Tumor Necrosis Factor Alpha-Induced Protein 3  (TNFAIP3) Modulates Enhancer Function and TNFAIP3 Gene Expression
Systemic Lupus Erythematosus – Human Etiology and Pathogenesis Poster II
9:00AM-11:00AM
Abstract Number: 2632
The Southern California Lupus Registry: I. Baseline Characteristics of Patients with Systemic Lupus Erythematosus in an Uncharted Territory
Systemic Lupus Erythematosus – Clinical Aspects and Treatment Poster III: Therapeutics and Clinical Trial Design
9:00AM-11:00AM
Abstract Number: 1983
The Types of Stress That Appear to Aggravate the Symptoms of Fibromyalgia
Fibromyalgia, Soft Tissue Disorders, Regional and Specific Clinical Pain Syndromes Poster II
9:00AM-11:00AM
Abstract Number: 2380
The Use of Fibroscan in Detecting Early Liver Fibrosis in RA Patients on Long Term MTX with Normal Liver Enzymes
Rheumatoid Arthritis – Clinical Aspects Poster III: Comorbidities
9:00AM-11:00AM
Abstract Number: 2517
The Usefulness of Trabecular Bone Score in Assessing the Bone Strength and Fracture Risk of Patients with Ankylosing Spondylitis
Spondyloarthropathies and Psoriatic Arthritis – Clinical Aspects and Treatment Poster III: Outcomes, Outcome Measures, and Comorbidities
  • «Previous Page
  • 1
  • …
  • 49
  • 50
  • 51
  • 52
  • 53
  • …
  • 65
  • Next Page»
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology